Cancer Care

 

 
IBCSG-24-02: A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer (SOFT)
Principal Investigator (?)
Study Number
C-SOFT
Summary
RATIONALE: Estrogen can stimulate the growth of breast tumor cells. Ovarian function
suppression combined with hormone therapy using tamoxifen or exemestane may fight breast
cancer by reducing the production of estrogen. It is not yet known whether suppression of
ovarian function plus either tamoxifen or exemestane is more effective than tamoxifen alone
in preventing the recurrence of hormone-responsive breast cancer.

PURPOSE: This randomized phase III trial is studying ovarian suppression with either
tamoxifen or exemestane to see how well they work compared to tamoxifen alone in treating
premenopausal women who have undergone surgery for hormone-responsive breast cancer.
Phase (?)
Phase III
Sponsor (?)
Available at the following location(s)

Southwestern Vermont

View more details from ClinicalTrials.gov.

Contact Information

For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:

Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.